🇺🇸 FDA
Pipeline program

Vortioxetine

210161

Approved small_molecule terminated

Quick answer

Vortioxetine for Type2 Diabetes is a Approved program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Type2 Diabetes
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials